Satsuma pulped as acute migraine drug flunks phase 3 trialShares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed Share XSatsuma pulped as acute migraine drug flunks phase 3 trialhttps://pharmaphorum.com/news/satsuma-pulped-as-acute-migraine-drug-flunks-phase-3-trial/
